Ascentage Pharma Group Intl ADR (AAPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||
| Net Income | -54,149 | -128,366 | N/A |
| Depreciation Amortization | 11,239 | 11,224 | N/A |
| Accounts receivable | 8,597 | -12,596 | N/A |
| Accounts payable and accrued liabilities | 2,674 | -3,181 | N/A |
| Other Working Capital | 15,202 | -1,259 | N/A |
| Other Operating Activity | 1,181 | 34,266 | 0 |
| Operating Cash Flow | $-15,256 | $-99,912 | $N/A |
| Cash Flows From Investing Activities | |||
| Change In Deposits | -2,192 | N/A | N/A |
| PPE Investments | -3,328 | -6,343 | N/A |
| Purchase Sale Intangibles | N/A | -1,477 | N/A |
| Other Investing Activity | -44,079 | 9,360 | 0 |
| Investing Cash Flow | $-49,599 | $3,017 | $N/A |
| Cash Flows From Financing Activities | |||
| Change In Short Term Borrowing | 73,421 | 131,206 | N/A |
| Common Stock Issued | 73,150 | 64,686 | N/A |
| Common Stock Repurchased | N/A | -815 | N/A |
| Other Financing Activity | -103,449 | -144,335 | 0 |
| Financing Cash Flow | $43,122 | $50,742 | $N/A |
| Exchange Rate Effect | 1,875 | 3,827 | N/A |
| Beginning Cash Position | 142,212 | 185,166 | N/A |
| End Cash Position | 122,354 | 142,840 | N/A |
| Net Cash Flow | $-19,858 | $-42,326 | $N/A |
| Free Cash Flow | |||
| Operating Cash Flow | -15,256 | -99,912 | N/A |
| Capital Expenditure | -3,328 | -6,345 | N/A |
| Free Cash Flow | -18,584 | -106,257 | 0 |